First described in the medical literature a century ago, only a handful of patients have since been diagnosed with disabling pansclerotic morphea, which causes severe skin lesions and poor wound healing, leading to deep scarring of all skin and muscle layers. The muscles eventually harden and break down and the joints stiffen, leading to reduced mobility. Because the disorder is so rare, there has been no standard treatment. Existing treatments designed to halt its progression often have severe side effects and are largely ineffective. People with disabling pansclerotic morphea typically live less than 10 years after diagnosis.

The disorder was originally thought to be caused by the immune system attacking the skin. Believing this to be an oversimplification, the researchers sought to learn the cause of the condition. Genome sequencing of four individuals with disabling pansclerotic morphea revealed that all four had genomic variants in the STAT4 gene, which encodes the STAT4 protein that helps turn genes on and off. The STAT4 protein also plays a role in fighting infections, and controls important aspects of wound-healing in the skin.

The scientists found that the STAT4 genomic variants resulted in an overactive STAT4 protein in the four patients, creating a harmful feedback loop of inflammation and impaired wound healing that worsened over time. To stop this feedback loop, they targeted Janus kinase (JAK), a family of enzymes in the inflammatory pathway that interact with STAT4. When treated with a JAK-inhibiting drug called ruxolitinib, the patients' rashes and ulcers improved dramatically.

The researchers concluded that ruxolitinib could be an effective treatment for patients with disabling pansclerotic morphea. "Our study provides an important new treatment option for these patients," co-first author Sarah Blackstone, a University of South Dakota medical student, said in a statement.

Other JAK inhibitors are commonly used to treat arthritis, eczema, ulcerative colitis, and other chronic inflammatory diseases. The researchers plan to continue studying other molecules in the inflammatory pathway and how they are altered in patients with disabling pansclerotic morphea and similar conditions. The team hopes to further the understanding of a broad array of more-common diseases.

"The findings of this study open doors for JAK inhibitors to be a potential treatment for other inflammatory skin disorders or disorders related to tissue scarring," senior author Dr. Dan Kastner, distinguished investigator at the National Institutes of Health and head of the National Human Genome Research Institute's Inflammatory Disease Section, said in a statement.

FDA approves first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa
The U.S. Food and Drug Administration (FDA) said on Friday it has approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for...

Software assembles complete genome sequences on-demand
National Institutes of Health (NIH) researchers have released an innovative software tool that makes assembling complete genome sequences from a variety...

New approach puts genotype first
NIH researchers have published an assessment of 13 studies that took a genotype-first approach to patient care, in contrast to the more typical phenotype-first...

Startup Mozart targets autoimmune, inflammatory diseases
Biopharmaceutical startup Mozart Therapeutics has launched with a focus on developing therapeutics for autoimmune and inflammatory diseases.

FDA issues EUA for Lilly's JAK inhibitor plus remdesivir for COVID-19
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the drug baricitinib, a janus kinase (JAK) inhibitor,...

Castle Creek begins gene therapy clinical trial for scleroderma
Castle Creek Biosciences has initiated a phase I/II clinical trial evaluating FCX-013, the company's investigational gene therapy for the treatment of...

Theravance's Janus kinase inhibitor enters phase I for ARDS
Biopharmaceutical company Theravance Biopharma has begun a phase I study in the U.K. for a drug to help prevent the development of acute respiratory distress...